Randomized Phase II Trial of Topotecan plus M6620 (VX-970) vs. Topotecan alone in Patients with Relapsed Small-Cell Lung Cancer

Brief description of study

The purpose of the study is to determine the efficacy of topotecan in combination with M6620 or topotecan alone for Relapsed Small-Cell Lung Cancer (SCLC) patients who have failed prior therapy. We want to know if M6620 and topotecan can improve survival compared to topotecan alone in patients with relapsed SCLC. M6620 (VX-970) is an ATP-competitive, highly potent, tightly binding inhibitor of ATR. The study drug M6620 is investigational, which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial.

Clinical Study Identifier: s20-01633
ClinicalTrials.gov Identifier: NCT03896503

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.